KERATINOCYTES--MODULATION BY RETINOIC ACID
角质细胞——视黄酸的调节
基本信息
- 批准号:3457306
- 负责人:
- 金额:$ 11.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-05-01 至 1995-04-30
- 项目状态:已结题
- 来源:
- 关键词:DNA footprinting acne aging basal cell carcinoma binding proteins chloramphenicol complementary DNA congenital ichthyosis cycloheximide decarboxylase inhibitor estrogen receptors fibronectins gel mobility shift assay gene induction /repression growth inhibitors keratinocyte light adverse effect messenger RNA nutrition related tag ornithine decarboxylase plasmids protein glutamine gamma glutamyltransferase psoriasis retinoate skin disorder skin disorder chemotherapy thymidine kinase transcription factor vitamin therapy
项目摘要
Retinoids are a class of compounds which are potent therapeutic agents for
a number of dermatological diseases. In order to improve treatment of
these diseases, it is necessary to elucidate the mechanism whereby
retinoids, such as all-trans-retinoic acid (RA), exert their anti-
proliferative effects. The long term goal of these studies is, therefore,
to determine how RA inhibits keratinocyte growth. An important action of
RA is keratinocytes is to inhibit ornithine decarboxylase (OD), an enzyme
whose products, the polyamines, are necessary for cell growth. It is
therefore proposed to determine if inhibition of ODC gene expression is a
direct consequence of retinoid action and how this repression is exerted.
These experiments re designed to test the hypothesis that RA suppresses ODC
gene transcription through a RA receptor (RAR)-mediated mechanism. This
will be examined by (1) determining the effects of RA and/or cycloheximide
on the relative transcription rates of the human ODC gene using run-on
transcription; (2) determining which RAR is expressed in keratinocytes and
discriminating between the actions of the cellular RA binding protein and
the alpha-, beta-, and gamma-RARs through the use of chimeric RAR/estrogen
receptors that will be transfected into keratinocytes; (3) identifying cis-
acting DNA elements that interact with trans-acting factors to cause RA-
mediated changes in ODC gene transcription, using in vitro footprinting,
gel retardation assays, and transfectin of isolated elements ligated to the
thymidine kinase-beta-globin gene; and (4) isolation of cDNAs encoding non-
RAR trans-acting factors which are implicated in RA action. Elucidation of
the mechanisms whereby RA suppresses ODC gene expression will yield
important information on how retinoids exert their anti-proliferative
effects.
类维A酸类化合物是一类有效的治疗药物。
一些皮肤病。为了提高治疗水平
这些疾病,有必要阐明其发病机制
类维甲酸,如全反式维甲酸(RA),发挥其抗
增殖效应。因此,这些研究的长期目标是,
以确定RA如何抑制角质形成细胞的生长。……的重要行动
RA是角质形成细胞,是抑制鸟氨酸脱羧酶(OD)的一种酶
其产物多胺是细胞生长所必需的。它是
因此提出了确定抑制ODC基因表达是否是一种
视黄醇作用的直接后果以及这种抑制是如何实施的。
这些实验旨在测试RA抑制ODC的假设
基因转录通过视黄酸受体(RAR)介导的机制。这
将通过(1)确定RA和/或放线菌亚胺的效果进行检查
用Run-On方法研究人ODC基因的相对转录速率
转录;(2)确定在角质形成细胞中表达哪些RAR和
区分细胞RA结合蛋白的作用和
通过使用嵌合的RAR/雌激素而产生的α、β和伽马受体
将被导入角质形成细胞的受体;(3)识别顺式-
与反式作用因子相互作用导致类风湿关节炎的作用DNA元件-
利用体外足迹,介导ODC基因转录的变化,
凝胶滞留试验和连接到细胞的分离元件的转染素
胸苷激酶-β-珠蛋白基因;(4)编码非核糖核酸的cDNA的分离
与RA作用有关的RAR反式作用因子。澄清:
RA抑制ODC基因表达的机制将导致
关于维甲酸如何发挥其抗增殖作用的重要信息
效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Noreen J Hickok其他文献
Noreen J Hickok的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Noreen J Hickok', 18)}}的其他基金
The joint environment and periprosthetic joint infection
关节环境与假体周围感染
- 批准号:
10744580 - 财政年份:2023
- 资助金额:
$ 11.45万 - 项目类别:
EXON-SPECIFIC FIBRONECTIN ISOFORMS AND CHONDROGENESIS
外显子特异性纤连蛋白异构体和软骨形成
- 批准号:
6375092 - 财政年份:2000
- 资助金额:
$ 11.45万 - 项目类别:
EXON-SPECIFIC FIBRONECTIN ISOFORMS AND CHONDROGENESIS
外显子特异性纤连蛋白异构体和软骨形成
- 批准号:
6648493 - 财政年份:2000
- 资助金额:
$ 11.45万 - 项目类别:
EXON-SPECIFIC FIBRONECTIN ISOFORMS AND CHONDROGENESIS
外显子特异性纤连蛋白异构体和软骨形成
- 批准号:
6511911 - 财政年份:2000
- 资助金额:
$ 11.45万 - 项目类别:
REGULATION OF HUMAN KERATINOCYTE GENE EXPRESSION BY TPA
TPA 对人类角质形成细胞基因表达的调节
- 批准号:
3162188 - 财政年份:1992
- 资助金额:
$ 11.45万 - 项目类别:
REGULATION OF HUMAN KERATINOCYTE GENE EXPRESSION BY TPA
TPA 对人类角质形成细胞基因表达的调节
- 批准号:
2080962 - 财政年份:1992
- 资助金额:
$ 11.45万 - 项目类别:
REGULATION OF HUMAN KERATINOCYTE GENE EXPRESSION BY TPA
TPA 对人类角质形成细胞基因表达的调节
- 批准号:
3162189 - 财政年份:1992
- 资助金额:
$ 11.45万 - 项目类别:
相似海外基金
Metagenomic discovery and optimization of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris
针对痤疮皮肤杆菌治疗寻常痤疮的新型内溶素的宏基因组发现和优化
- 批准号:
10821291 - 财政年份:2023
- 资助金额:
$ 11.45万 - 项目类别:
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
用于口服治疗顽固性结节性痤疮的选择性 CYP26 抑制剂。
- 批准号:
10822482 - 财政年份:2023
- 资助金额:
$ 11.45万 - 项目类别:
ENLIGHT : Light-sensitive Engineered Living Material for acne therapy
ENLIGHT:用于痤疮治疗的光敏工程活性材料
- 批准号:
EP/Y03029X/1 - 财政年份:2023
- 资助金额:
$ 11.45万 - 项目类别:
Fellowship
Developing a novel medical-grade microneedle patch to treat acne vulgaris
开发一种新型医用级微针贴片来治疗寻常痤疮
- 批准号:
10053162 - 财政年份:2023
- 资助金额:
$ 11.45万 - 项目类别:
Collaborative R&D
Smart Photodynamic Therapy for Acne by Reversibly Switchable Intersystem Crossing in Pure Organic Materials
通过纯有机材料中的可逆可切换系间交叉来治疗痤疮的智能光动力疗法
- 批准号:
10483461 - 财政年份:2022
- 资助金额:
$ 11.45万 - 项目类别:
Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris
寻常痤疮中 Th17 细胞外陷阱介导的抗菌宿主防御
- 批准号:
10502200 - 财政年份:2022
- 资助金额:
$ 11.45万 - 项目类别:
Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris
寻常痤疮中 Th17 细胞外陷阱介导的抗菌宿主防御
- 批准号:
10698121 - 财政年份:2022
- 资助金额:
$ 11.45万 - 项目类别:
Acne: a disease of lipid metabolism, microbiome and the immune response
痤疮:一种脂质代谢、微生物组和免疫反应疾病
- 批准号:
10404440 - 财政年份:2022
- 资助金额:
$ 11.45万 - 项目类别:
Acne: a disease of lipid metabolism, microbiome and the immune response
痤疮:一种脂质代谢、微生物组和免疫反应疾病
- 批准号:
10404436 - 财政年份:2022
- 资助金额:
$ 11.45万 - 项目类别:
A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women
螺内酯与盐酸强力霉素治疗女性痤疮的随机、双盲、多中心比较疗效研究
- 批准号:
10296086 - 财政年份:2021
- 资助金额:
$ 11.45万 - 项目类别:














{{item.name}}会员




